Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models-Reference-Cited by-同舟云学术

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models

Published:2014-01-08 Issue:2 Volume:6 Page:556-566
ISSN:1942-0870
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Whiteman Kathleen R,Johnson Holly A,Mayo Michele F,Audette Charlene A,Carrigan Christina N,LaBelle Alyssa,Zukerberg Lawrence,Lambert John M,Lutz Robert J

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.27756

Reference46 articles.

1. American Cancer Society. ACS, Cancer Facts and Figures 2010. ACS, Cancer Facts and Figures 2010. Atlanta, 2010.

2. Treatment options for small cell lung cancer – do we have more choice?

3. Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

4. Small cell lung cancer

5. Topotecan in the treatment of relapsed small cell lung cancer

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates treatment of small cell lung cancer: advances in clinical research;Discover Oncology;2024-08-01

2. Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy;Antibodies;2023-11-03

3. Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions;Journal of Translational Medicine;2023-07-14

4. Cancer Cell‐Specific Fluorescent Prodrug Delivery Platforms;Advanced Science;2023-04-07

5. A novel combination for the treatment of small cell lung cancer: Active targeted irinotecan and stattic co-loaded PLGA nanoparticles;International Journal of Pharmaceutics;2023-02